Back to search
FDAFDA · Food and drugs·Recall number D-1504-2012

DMPS 250MG/10ML INJECTABLE 20 ML, 30 ML; DMPS 50MG/ML (500MG/10ML) INJECTABLE 10 ML, 5 ML (4 DIFFERENT PRODUCTS)

Published August 22, 2012 · Recall initiated: May 25, 2012

Summary

FDA records drug Class II recall D-1504-2012, published August 22, 2012 and initiated May 25, 2012. Recalling firm: Franck's Lab Inc., d.b.a. Franck's Compounding Lab; Status: Terminated; Reported quantity: 6 units; Lot: Rx #'s: 0405733 0353173 0349837 0392673. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Franck's Lab Inc., d.b.a. Franck's Compounding Lab
Distributor
Nationwide, Bahamas, Columbia, Dominican Republic, Grand Cayman, Guatemala, Poland, Santo Domingo, Venezuela, and West Indies
Lot
Rx #'s: 0405733 0353173 0349837 0392673
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was DMPS 250MG/10ML INJECTABLE 20 ML, 30 ML; DMPS 50MG/ML (500MG/10ML) INJECTABLE 10 ML, 5 ML (4 DIFFERENT PRODUCTS) recalled?

Yes. FDA published recall D-1504-2012 on August 22, 2012. Reported hazard: Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.

What should I do if I have this product?

Voluntary: Firm initiated · Letter